Please login to the form below

Not currently logged in

Allergy Therapeutics

This page shows the latest Allergy Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Nestlé Health Science invests $145m in food allergy biotech

Nestlé Health Science invests $145m in food allergy biotech

Nestlé Health Science invests $145m in food allergy biotech. Aimmune Therapeutics' lead product is a phase III peanut allergy treatment. ... An oral biologic containing the protein profile found in peanuts, AR101 is designed to desensitise patients with

Latest news

  • Consilium wins Allergy Therapeutics account Consilium wins Allergy Therapeutics account

    Consilium wins Allergy Therapeutics account. Will advise the firm on international investor relations. ... Consilium Strategic Communications has been appointed by specialty pharmaceutical firm Allergy Therapeutics as its international investor relations

  • Leaning forward

    Leaning forward. Allergy Therapeutics used lean management tools to make their Odyssey of improvement. ... Allergy Therapeutics develops, manufactures and sells a range of pharmaceutical products for the treatment and prevention of allergy.

  • Yo-yoing

    Shares in Allergy Therapeutics, a specialist pharmaceutical company that focuses on allergy vaccination, benefited from news that it has achieved a positive outcome for its key clinical efficacy and safety study ... R204, which marks an important step in

  • Forging ahead

    Positive results from ongoing phase II trials of Trinam, Ark Therapeutics' novel gene therapy to prevent blood vessels blocking in kidney dialysis patients who have undergone vascular access graft surgery, were ... Shares in biopharmaceutical company

  • Up and up?

    AIM. On the Alternative Investment Market (AIM), Allergy Therapeutics stole the limelight with its shares jumping by more than a fifth over the past week.

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    587.5. Santaris/ Roche (pRED). Company acquisition. Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics. ... 183. Immune Design/ Sanofi. Licence. GLAAS discovery platform to develop therapeutics for a selected food allergy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...